Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health problems news

Show

From To
Effect of Depression, Lifestyle on Cognitive Function in PLWHIV

Compared with patients without HIV, the poorer cognitive performances of PLWHIV were partly mediated by a higher prevalence of depressive symptoms.

Published
26 March 2019
From
Infectious Disease Advisor
Diet and exercise advice lowers diabetes risk in people with HIV

Rates of diabetes are higher in people living with HIV than in the general population, but individualised lifestyle advice from a dietitian led to clinically and statistically

Published
26 March 2019
By
Roger Pebody
The impact of older antiretrovirals on fat redistribution and cardiovascular risk factors may be irreversible

Fat redistribution in people with HIV who have ever taken thymidine analogues and/or didanosine (TA/ddI) can persist through time, while increasing cardiovascular risk factors, according to a Danish

Published
21 March 2019
By
Alain Volny-Anne
On-Demand PrEP With TDF/FTC Not Associated With Clinically Relevant Decline in Kidney Function

On-demand pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is not associated with a significant relevant in kidney function, especially among young people with low pill use and high baseline estimated glomerular filtration rate, investigators in France found.

Published
20 March 2019
From
Contagion Live
TB CAB statement on safety of using bedaquiline and delamanid together

he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

Published
14 March 2019
From
TB Online
Higher HIV viral load and lower CD4 count linked to liver cancer risk

People living with HIV who have a longer duration of detectable viral load and those with low CD4 cell counts have a higher likelihood of developing liver

Published
13 March 2019
By
Liz Highleyman
Large French study examines neuropsychiatric side effects with integrase inhibitors

The largest prospective study to date on integrase inhibitors and their potential for being associated with neuropsychiatric side effects was conducted in France. With more than 21,000 HIV-positive participants, the study found that the proportion of people who stopped taking integrase inhibitors due to neuropsychiatric side effects was generally very low (between 1% and 3%). Of particular note is the fact that before starting treatment with an integrase-inhibitor-containing regimen, between 3% and 10% of participants had previously reported neuropsychiatric side effects with other classes of HIV treatment.

Published
12 March 2019
From
CATIE
People with HIV may benefit from earlier lung cancer screening

People living with HIV, especially women, may develop lung cancer at an earlier age and with a less extensive smoking history than people in the general population,

Published
12 March 2019
By
Liz Highleyman
Are CD4 counts still useful in the 'treat all' era?

CD4 cell testing before starting treatment is still essential even in the era of 'treat all' guidelines, two studies from southern Africa presented at the Conference on

Published
08 March 2019
By
Keith Alcorn
'Patient No. 1' from a Hep C heart transplant study shares his story

By the time three transplant physicians approached Tom Giangiulio Jr. about being the first patient in a new clinical trial to accept a heart from a Hepatitis C-positive donor, Giangiulio didn’t have much of a choice.

Published
08 March 2019
From
Cardiovascular Business

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.